Urinary expression of let-7c cluster as non-invasive tool to assess the risk of disease progression in patients with high grade non-muscle invasive bladder Cancer: a pilot study.
Let-7c cluster, urinary biomarkers, progression free survival
Non-muscle-invasive bladder cancer
microRNA
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
17 Apr 2020
17 Apr 2020
Historique:
received:
04
01
2020
accepted:
19
02
2020
entrez:
19
4
2020
pubmed:
19
4
2020
medline:
22
1
2021
Statut:
epublish
Résumé
High grade non-muscle-invasive bladder cancer (HG-NMIBC) is a heterogeneous disease with variable risk of progression. Urinary microRNAs are promising biomarkers for BC detection and surveillance. Let-7c-5p miRNA, clustered with miR-99a-5p and -125b-5p, is deregulated in cancer, including BC. The aim of this study is to evaluate urinary let-7c cluster expression in Ta/T1 HG-NMIBC patients and its impact on progression-free survival (PFS). Quantitative Real-Time-Polymerase-Chain-Reaction (qRT-PCR) was used to analyze the let-7c cluster expression in 57 urine and 49 neoplastic paired tissue samples prospectively collected from transurethral resection (TUR) HG-NMIBC patients. Twenty urine and 10 bladder tissue samples were collected and analyzed as normal controls. QRT-PCR was also used to detect intra-/extra-cellular let-7c cluster in BC cells. Receiver Operating Characteristic (ROC) curves were used to identify urinary miRNAs cut-off values predicting T-stage and PFS. Uni/multivariable Cox regression was performed to identify predictors of PFS. A nomogram predicting progression risk and a decision curve analysis (DCA) were performed. Urinary let-7c was significantly up-regulated in patients compared with controls, while the whole cluster was down-regulated in tumor tissues. Supporting these findings, in vitro comparison of extra-/intra-cellular ratios of cluster levels between BC cells, showed a higher ratio for let-7c in HG-NMIBC versus low-grade cells. Urinary let-7c cluster expression was increased in higher T-stage and was an independent predictor of progression. Lower EORTC-score and downregulation of urinary cluster were predictors of higher PFS on univariable Cox regression, while on multivariable analysis only cluster expression was an independent progression predictor. On DCA, a benefit was evident for patients with a PFS probability > 20%. Urinary let-7c cluster evaluation may improve prognosis, identifying patients at risk of progression and addressing early radical treatment.
Sections du résumé
BACKGROUND
BACKGROUND
High grade non-muscle-invasive bladder cancer (HG-NMIBC) is a heterogeneous disease with variable risk of progression. Urinary microRNAs are promising biomarkers for BC detection and surveillance. Let-7c-5p miRNA, clustered with miR-99a-5p and -125b-5p, is deregulated in cancer, including BC. The aim of this study is to evaluate urinary let-7c cluster expression in Ta/T1 HG-NMIBC patients and its impact on progression-free survival (PFS).
METHODS
METHODS
Quantitative Real-Time-Polymerase-Chain-Reaction (qRT-PCR) was used to analyze the let-7c cluster expression in 57 urine and 49 neoplastic paired tissue samples prospectively collected from transurethral resection (TUR) HG-NMIBC patients. Twenty urine and 10 bladder tissue samples were collected and analyzed as normal controls. QRT-PCR was also used to detect intra-/extra-cellular let-7c cluster in BC cells. Receiver Operating Characteristic (ROC) curves were used to identify urinary miRNAs cut-off values predicting T-stage and PFS. Uni/multivariable Cox regression was performed to identify predictors of PFS. A nomogram predicting progression risk and a decision curve analysis (DCA) were performed.
RESULTS
RESULTS
Urinary let-7c was significantly up-regulated in patients compared with controls, while the whole cluster was down-regulated in tumor tissues. Supporting these findings, in vitro comparison of extra-/intra-cellular ratios of cluster levels between BC cells, showed a higher ratio for let-7c in HG-NMIBC versus low-grade cells. Urinary let-7c cluster expression was increased in higher T-stage and was an independent predictor of progression. Lower EORTC-score and downregulation of urinary cluster were predictors of higher PFS on univariable Cox regression, while on multivariable analysis only cluster expression was an independent progression predictor. On DCA, a benefit was evident for patients with a PFS probability > 20%.
CONCLUSIONS
CONCLUSIONS
Urinary let-7c cluster evaluation may improve prognosis, identifying patients at risk of progression and addressing early radical treatment.
Identifiants
pubmed: 32303246
doi: 10.1186/s13046-020-01550-w
pii: 10.1186/s13046-020-01550-w
pmc: PMC7164295
doi:
Substances chimiques
Biomarkers, Tumor
0
MicroRNAs
0
mirnlet7 microRNA, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
68Références
Urol Oncol. 2018 Dec;36(12):531.e1-531.e8
pubmed: 30322728
Neoplasma. 2016;63(5):799-808
pubmed: 27468885
Eur Urol. 2017 Mar;71(3):447-461
pubmed: 27324428
J Exp Clin Cancer Res. 2019 Oct 29;38(1):433
pubmed: 31665050
J Exp Clin Cancer Res. 2018 May 2;37(1):95
pubmed: 29716630
Nat Rev Urol. 2015 Apr;12(4):225-35
pubmed: 25800393
PLoS One. 2012;7(3):e32832
pubmed: 22479342
Signal Transduct Target Ther. 2016 Jan 28;1:15004
pubmed: 29263891
Can Urol Assoc J. 2013 Jan-Feb;7(1-2):28-32
pubmed: 22630336
Int J Mol Sci. 2018 Aug 24;19(9):
pubmed: 30149597
Trends Biochem Sci. 2012 Nov;37(11):460-5
pubmed: 22944280
PLoS One. 2009;4(5):e5532
pubmed: 19440243
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7
pubmed: 16442208
J Exp Clin Cancer Res. 2015 May 21;34:53
pubmed: 25991007
BMC Med. 2015 Feb 17;13:33
pubmed: 25855867
Eur Urol. 2016 Jan;69(1):60-9
pubmed: 26210894
Front Oncol. 2019 Aug 07;9:729
pubmed: 31448232
J Exp Clin Cancer Res. 2019 May 22;38(1):212
pubmed: 31118065
Cancer Sci. 2011 Mar;102(3):522-9
pubmed: 21166959
Int J Mol Sci. 2016 Apr 27;17(5):
pubmed: 27128908
PLoS One. 2010 Oct 08;5(10):e13247
pubmed: 20949044
Oncol Lett. 2018 Apr;15(4):5056-5070
pubmed: 29616090
Endocr Relat Cancer. 2010 Jan 29;17(1):F19-36
pubmed: 19779035
Nat Rev Urol. 2016 Dec;13(12):734-752
pubmed: 27804986
Genes Cancer. 2016 Mar;7(3-4):86-97
pubmed: 27382433
Clin Genitourin Cancer. 2014 Aug;12(4):278-86
pubmed: 24331576
Oncotarget. 2018 Apr 17;9(29):20658-20669
pubmed: 29755679
Int J Cancer. 2012 Nov 15;131(10):2215-22
pubmed: 22618667
Mol Cancer Res. 2014 Jun;12(6):878-89
pubmed: 24637061